Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (331-340 of 362) with videos related to

Pageof 37
Sort By:
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure|May 4, 2022
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registryNina Jakus, Jasper J Brugts, Brian Claggett, et al.
Nature Medicine|March 18, 2023
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
European Journal of Heart Failure|April 16, 2026
Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor DataFrederik Holme Fussing, Lise Witten Davodian, Danny Witten Davodian, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.
Pageof 37

Showing results (331-340 of 362) with videos related to

Sort By:
Pageof 37
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure|May 4, 2022
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registryNina Jakus, Jasper J Brugts, Brian Claggett, et al.
Nature Medicine|March 18, 2023
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
European Journal of Heart Failure|April 16, 2026
Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor DataFrederik Holme Fussing, Lise Witten Davodian, Danny Witten Davodian, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.
Pageof 37